Literature DB >> 10500966

[Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 in patients with renal cell carcinoma].

T Hioki1, Y Sugimura.   

Abstract

Detection of circulating cancer cells in peripheral blood may improve cancer staging and monitoring. This study was undertaken to investigate the clinical implications of detection of circulating cancer cells in renal cancer patients. Cytokeratin-19 (CK19) mRNA was amplified by nested reverse transcription-polymerase chain reaction (RT-PCR) in the peripheral blood of 33 healthy volunteers and 19 patients with renal cell carcinoma. The detection limit of the method was 10 cancer cells in 10(7) peripheral blood mononuclear cells. The positive detection rate was 47% for renal cancer patients and 9% for healthy volunteers. The number of patients expressing CK19 mRNA in each clinical stage was 0 out of 3 patients in stage 1; 2 out of 8 (25%) in stage 2; 3 out of 4 (75%) in stage 3; 4 out 4 (100%) in stage 4. A significant correlation was seen between CK19 mRNA expression and clinical stage (p = 0.0023). This method may be useful for early detection of micrometastasis, and facilitate the design of better therapeutic strategies for the treatment of renal cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500966

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  3 in total

Review 1.  Detection and isolation of circulating tumor cells in urologic cancers: a review.

Authors:  Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

2.  Circulating and disseminated tumor cells in the management of advanced prostate cancer.

Authors:  Stephan Kruck; Georgios Gakis; Arnulf Stenzl
Journal:  Adv Urol       Date:  2011-08-21

3.  B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma.

Authors:  Xiaojian Qin; Hailiang Zhang; Dingwei Ye; Bo Dai; Yao Zhu; Guohai Shi
Journal:  Onco Targets Ther       Date:  2013-11-15       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.